OGT to showcase new RNA-Seq Service in live Webinar
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will host a live webinar on Thursday 15th November (3pm BST). Dr Daniel Swan, Senior NGS Computational Biologist at OGT, will discuss how RNA-Seq is revolutionising the field of transcriptomics by delivering unprecedented biological insight into the way cells function. He will also explain how this can only be reliably achieved through good experimental design — ensuring the data generated represents the true biology — and rigorous data analysis procedures.
The 45-minute webinar will be essential viewing for everyone interested in learning why RNA-Seq delivers novel biological discoveries and how best to design an NGS gene expression study that delivers true biological insight. As part of the webinar, Dr Swan will utilise OGT’s NGS data reporting interface, which makes it quick, easy and intuitive to visualise gene and transcript expression levels, identify isoforms and perform SNP and indel analysis for a range of eukaryotes.
To register for the webinar, please visit the sign-up page.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: email@example.com
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.